Protein degradation reaches further out
nature.com · 474 words · saved by 1 readers
Discover the world’s best science and medicine | Nature.com
Email Bluesky Facebook LinkedIn Reddit Whatsapp X Access through your institution Buy or subscribe Although the development of efficient and selective small-molecule inhibitors and monoclonal antibodies has improved over the years, ‘undruggable’ proteins can still elude these established drug modalities. Targeted protein degradation with proteolysis-targeting chimaeras (PROTACs) has emerged as an attractive route to target these difficult proteins. However, this approach is limited to proteins that have intracellular domains, meaning that ~40% of the proteome is out of scope. Now, Bertozzi and
saved by
related reading
- Lysosome-targeting chimaeras for degradation of extracellular proteins | Naturenature.com
- Lysosome-targeting chimeras evolve | Nature Chemical Biologynature.com
- Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
- PDB101: Molecule of the Month: PROTACs and Molecular Glue Degraderspdb101.rcsb.org
- Development of a targeted BioPROTAC degrader selective for misfolded SOD1nature.com
- The dTAG system for immediate and target-specific protein degradationpmc.ncbi.nlm.nih.gov
- Gap Mapgap-map.org
- Topos Bio - Redefining Druggable Spacetoposbio.ai
- Engineering Plastic-Degrading Enzymes and PCSK9 Binders with Protein AI Toolsblog.latch.bio
- Mesa — JURA Bio, Inc.jura.bio
- AlphaProteo generates novel proteins for biology and health researchdeepmind.google
- Protein World Model | Biohubbiohub.ai